Hexal Sues EMA Over Refusal To Accept Generic Aubagio Filing
Executive Summary
Hexal is challenging a decision by the European Medicines Agency to reject its application for a generic version of Sanofi’s MS drug Aubagio, raising fresh questions about how a new active substance is defined. By contrast, a generic version from Glenmark was recently approved in the US.